Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT84ETX)

• DTT Name: Human immunodeficiency virus Reverse transcriptase (HIV RT) DTT Info
• Gene Name: HIV RT

Molecule-Related Drug & Molecule List

19 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[1]
Adefovir Dipivoxil	DMMAWY1	Hepatitis B virus infection	1E51.0	Approved	[2]
Bictegravir, emtricitabine and tenofovir alafenamide	DMG0H8K	Human immunodeficiency virus infection	1C62	Approved	[3]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[2]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[4]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[2]
Emtricitabine	DMBMUWZ	Hepatitis virus infection	1E50-1E51	Approved	[5]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[6]
GS-7340	DM1ECNJ	Hepatitis B virus infection	1E51.0	Approved	[7]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[2]
MK-1439	DM215WE	Human immunodeficiency virus infection	1C62	Approved	[3]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[8]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[9]
Sorivudine	DMUJGR1	Virus infection	1A24-1D9Z	Approved	[10]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[11]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[12]
Tenofovir disoproxil fumarate	DMSY4ZG	Discovery agent	N.A.	Approved	[5]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[13]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[12]

35 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apricitabine	DM1K78U	Human immunodeficiency virus infection	1C62	Phase 3	[14]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[15]
Glyminox	DMQCZ4N	Sexually transmitted infection	1A9Z	Phase 3	[16]
PT-304	DMMJ63A	N. A.	N. A.	Phase 3	[17]
VM-1500	DM4WQBO	Human immunodeficiency virus infection	1C62	Phase 2/3	[18]
Alovudine	DMJPV5X	Breast cancer	2C60-2C65	Phase 2	[14]
Amdoxovir	DMEB3T9	Hepatitis B virus infection	1E51.0	Phase 2	[19]
BILR-355	DMAG4SX	Human immunodeficiency virus infection	1C62	Phase 2	[20]
EMIVIRINE	DMQH1NV	Human immunodeficiency virus infection	1C62	Phase 2	[21]
F4co vaccine	DM6UQNW	Human immunodeficiency virus infection	1C62	Phase 2	[22]
IDX899	DMSRC5D	Human immunodeficiency virus infection	1C62	Phase 2	[23]
L-697,661	DMB7WT1	Human immunodeficiency virus infection	1C62	Phase 2	[24]
Lersivirine	DMSEVBH	Human immunodeficiency virus infection	1C62	Phase 2	[25]
Lexipafant	DMZ2YBE	Nerve injury	ND56.4	Phase 2	[9]
OBP-601	DMVXZC4	Human immunodeficiency virus-1 infection	1C62	Phase 2	[26]
RALURIDINE	DMBFZSX	Human immunodeficiency virus infection	1C62	Phase 2	[27]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[28]
Dapivirine	DMJPSIL	Human immunodeficiency virus infection	1C62	Phase 1/2	[9]
TRICIRIBINE	DM8IC5H	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[29]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[28]
AIC-292	DMNHBMC	Human immunodeficiency virus infection	1C62	Phase 1	[30]
ATEVIRDINE	DM96JTX	Human immunodeficiency virus infection	1C62	Phase 1	[31]
CALANOLIDE A	DMQTUH8	Mycobacterium infection	1B10-1B21	Phase 1	[32]
Capravirine	DM9ERH1	Human immunodeficiency virus infection	1C62	Phase 1	[33]
CMX-157	DMMF0J3	Human immunodeficiency virus infection	1C62	Phase 1	[34]
GW-695634	DMBDW93	Human immunodeficiency virus infection	1C62	Phase 1	[35]
KM-023	DME8DUV	Human immunodeficiency virus infection	1C62	Phase 1	[36]
MK-6186	DMSA27Z	Human immunodeficiency virus infection	1C62	Phase 1	[37]
MK-8504	DMHTWBL	Human immunodeficiency virus-1 infection	1C62	Phase 1	[38]
MK-8583	DMQHPME	Human immunodeficiency virus-1 infection	1C62	Phase 1	[39]
MSH-372	DMEP7HO	Human immunodeficiency virus infection	1C62	Phase 1	[40]
PT-112	DMB6M1P	Multiple myeloma	2A83	Phase 1	[41]
PT-302	DMWBA1S	N. A.	N. A.	Phase 1	[17]
TROVIRDINE HYDROCHLORIDE	DMDSF0Q	Human immunodeficiency virus infection	1C62	Phase 1	[42]
UC-781	DM5XMHB	Human immunodeficiency virus infection	1C62	Phase 1	[43]

36 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lobucavir	DM8OMI6	Virus infection	1A24-1D9Z	Discontinued in Phase 3	[44]
AZT-P-DDI	DM04CIK	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[45]
DMP-961	DMI5XKC	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[46]
Elvucitabine	DMM5WQL	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[47]
FOZIVUDINE TIDOXIL	DMUD0IN	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[48]
L-696229	DM54I8A	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[49]
Lodenosine	DMGZ3BF	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[50]
Loviride	DMD16VS	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[51]
Opaviraline	DMP0ARJ	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[52]
R-18893	DMGVRQ2	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[53]
DPC-082	DMSOHR6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[54]
L-697639	DMBIR5P	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[55]
LY-73497	DMB1OAR	N. A.	N. A.	Discontinued in Phase 1	[17]
PNU-142721	DMPWG2K	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[56]
R-82150	DMTK3DR	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[57]
R-82913	DM4WJHY	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[58]
A-79296	DM3IYMF	Herpes simplex virus infection	1F00	Terminated	[59]
ANX-201	DMOJP9E	Cytomegalovirus infection	1D82	Terminated	[60]
BAY-Z-4305	DMZGFM6	Human immunodeficiency virus-1 infection	1C62	Terminated	[61]
BEA-005	DM6KRJW	Cytomegalovirus infection	1D82	Terminated	[62]
C-AFG	DMJQ3WR	Virus infection	1A24-1D9Z	Terminated	[63]
DMP-963	DMKU469	Human immunodeficiency virus infection	1C62	Terminated	[46]
DPC-A78277	DM67VDK	Human immunodeficiency virus infection	1C62	Terminated	[64]
GS-9148	DMCYZL3	Human immunodeficiency virus infection	1C62	Terminated	[65]
ISIS-1082	DMD6SXO	Virus infection	1A24-1D9Z	Terminated	[66]
MEN-10690	DM57S3D	Human immunodeficiency virus-1 infection	1C62	Terminated	[67]
MEN-10880	DMKS1W0	Human immunodeficiency virus-1 infection	1C62	Terminated	[67]
MEN-10979	DM6UYN1	Human immunodeficiency virus-1 infection	1C62	Terminated	[68]
MIV-170	DMT9QB5	Human immunodeficiency virus infection	1C62	Terminated	[69]
MSC-204	DMNYLEU	Human immunodeficiency virus infection	1C62	Terminated	[40]
Navuridine	DM8FB6E	Human immunodeficiency virus infection	1C62	Terminated	[70]
RDEA-427	DM08BUV	Human immunodeficiency virus infection	1C62	Terminated	[71]
RDEA-640	DM61RGQ	Human immunodeficiency virus infection	1C62	Terminated	[72]
SPD-756	DM9HFV7	Human immunodeficiency virus infection	1C62	Terminated	[73]
UC-38	DM0Z7PK	Human immunodeficiency virus infection	1C62	Terminated	[74]
UC-84	DMY9UEZ	Human immunodeficiency virus infection	1C62	Terminated	[75]

117 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DMER0IY	Discovery agent	N.A.	Investigative	[76]
1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea	DM0K2T1	Discovery agent	N.A.	Investigative	[17]
1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea	DMC1IKP	Discovery agent	N.A.	Investigative	[76]
1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DMXG10E	Discovery agent	N.A.	Investigative	[17]
1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea	DM4B2EN	Discovery agent	N.A.	Investigative	[17]
1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DM37RI9	Discovery agent	N.A.	Investigative	[17]
1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea	DMIGDCK	Discovery agent	N.A.	Investigative	[17]
1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea	DM9EK3T	Discovery agent	N.A.	Investigative	[17]
1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea	DM60Y8M	Discovery agent	N.A.	Investigative	[76]
1-Benzenesulfonyl-2-nitro-benzene	DM781L6	Discovery agent	N.A.	Investigative	[77]
1-Benzothiazol-2-yl-3-phenethyl-thiourea	DMEZPC8	Discovery agent	N.A.	Investigative	[17]
1-Benzyl-3-thiazol-2-yl-thiourea	DMNWGOE	Discovery agent	N.A.	Investigative	[17]
1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea	DMF4BCP	Discovery agent	N.A.	Investigative	[76]
1-nitro-2-(2-nitrophenylsulfonyl)benzene	DMP6VOK	Discovery agent	N.A.	Investigative	[77]
1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea	DM32WSM	Discovery agent	N.A.	Investigative	[17]
1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea	DMAQKO1	Discovery agent	N.A.	Investigative	[17]
1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea	DMCIA40	Discovery agent	N.A.	Investigative	[76]
10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DM1JLUV	Discovery agent	N.A.	Investigative	[78]
10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMGT82V	Discovery agent	N.A.	Investigative	[78]
10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMCXA1Y	Discovery agent	N.A.	Investigative	[78]
10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMD1258	Discovery agent	N.A.	Investigative	[78]
10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one	DMZ3N8A	Discovery agent	N.A.	Investigative	[78]
2',3'-ddATP	DMOB7P6	Discovery agent	N.A.	Investigative	[79]
2'-3'-dideoxy-7-deaza-guaninetriphosphate	DM74X5O	Discovery agent	N.A.	Investigative	[79]
2'-deoxythymidine triphosphate	DM9OEJT	Discovery agent	N.A.	Investigative	[79]
2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile	DM3VJEZ	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile	DMFW9D3	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile	DM7391H	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile	DM8O6AC	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile	DMRKQLV	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile	DM8UQD5	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile	DMBMK8S	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile	DM0N5J4	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile	DM6R98Y	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile	DMTUM78	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile	DMH4TRD	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile	DM9XKJQ	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile	DMT3KP0	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile	DM9GQ1U	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile	DM2MCK1	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile	DMG7HP2	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile	DMACYWZ	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile	DML6EFV	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile	DMXPWHF	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile	DMMKJYG	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(toluene-2-sulfonyl)-benzonitrile	DMWGE3U	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(toluene-3-sulfinyl)-benzonitrile	DMJXWH0	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(toluene-3-sulfonyl)-benzonitrile	DM1EGP9	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-(toluene-4-sulfonyl)-benzonitrile	DMB7415	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-benzenesulfonyl-benzonitrile	DMJ4H9F	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-m-tolylsulfanyl-benzonitrile	DMQF9H1	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-p-tolylsulfanyl-benzonitrile	DM4BQ1W	Discovery agent	N.A.	Investigative	[77]
2-Amino-6-phenylsulfanyl-benzonitrile	DMMBGK0	Discovery agent	N.A.	Investigative	[77]
2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine	DM6F0C4	Discovery agent	N.A.	Investigative	[80]
3'thiacytidine	DM2K59V	Discovery agent	N.A.	Investigative	[81]
3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one	DMB4WP5	Discovery agent	N.A.	Investigative	[82]
6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one	DM0CZ1F	Discovery agent	N.A.	Investigative	[83]
6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one	DMZRQEF	Discovery agent	N.A.	Investigative	[84]
6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one	DMI5RNJ	Discovery agent	N.A.	Investigative	[83]
6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one	DM7ANE3	Discovery agent	N.A.	Investigative	[84]
Benzimidazole 5-carboxamide	DM75U9X	Hepatovirus infection	1E51	Investigative	[9]
CORILAGIN	DMAC698	Discovery agent	N.A.	Investigative	[85]
Deoxyfluorothymidine	DMKFMRY	Discovery agent	N.A.	Investigative	[81]
Dihydropyrone	DMYSPMH	Hepatovirus infection	1E51	Investigative	[9]
E-EBU-dM	DMN8JKX	Discovery agent	N.A.	Investigative	[86]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM3FH02	Discovery agent	N.A.	Investigative	[87]
Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DMQ0XYH	Discovery agent	N.A.	Investigative	[87]
Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM82X3J	Discovery agent	N.A.	Investigative	[87]
HEPT	DMK846H	Discovery agent	N.A.	Investigative	[88]
HI-172	DMCKAWY	Discovery agent	N.A.	Investigative	[89]
HI-236	DM3R4ZF	Discovery agent	N.A.	Investigative	[90]
HI-240	DMQK5RM	Discovery agent	N.A.	Investigative	[91]
HI-241	DMTKCW6	Discovery agent	N.A.	Investigative	[90]
HI-242	DM0QYLP	Discovery agent	N.A.	Investigative	[90]
HI-244	DMG36BD	Discovery agent	N.A.	Investigative	[76]
HI-280	DME4SML	Discovery agent	N.A.	Investigative	[89]
HI-281	DM7K0PH	Discovery agent	N.A.	Investigative	[89]
HI-443	DMSUWD8	Discovery agent	N.A.	Investigative	[91]
HI-445	DMYP0DE	Discovery agent	N.A.	Investigative	[89]
Indole N -acetamide	DMEHI15	Hepatovirus infection	1E51	Investigative	[9]
ISODISPAR B	DM7ZSVD	Discovery agent	N.A.	Investigative	[92]
NSC-380292	DMHO40Q	Discovery agent	N.A.	Investigative	[93]
NSC-625487	DM63G4R	Human immunodeficiency virus infection	1C62	Investigative	[94]
PT-101	DM47F9I	Discovery agent	N.A.	Investigative	[17]
PT-102	DMD0K61	Discovery agent	N.A.	Investigative	[90]
PT-103	DM0LTB2	Discovery agent	N.A.	Investigative	[17]
PT-104	DMABLF7	Discovery agent	N.A.	Investigative	[41]
PT-106	DMPX71O	Discovery agent	N.A.	Investigative	[17]
PT-108	DMBLAV4	Discovery agent	N.A.	Investigative	[17]
PT-109	DM8PX1T	Discovery agent	N.A.	Investigative	[41]
PT-110	DMEIW5T	Discovery agent	N.A.	Investigative	[41]
PT-113	DMUFC6V	Discovery agent	N.A.	Investigative	[41]
PT-114	DMYE1P8	Discovery agent	N.A.	Investigative	[41]
PT-115	DMS01IN	Discovery agent	N.A.	Investigative	[41]
PT-306	DME0N2Z	Discovery agent	N.A.	Investigative	[17]
PT-307	DM45HVR	Discovery agent	N.A.	Investigative	[17]
PT-308	DM7FM8V	Discovery agent	N.A.	Investigative	[17]
PT-309	DM7TILD	Discovery agent	N.A.	Investigative	[17]
PT-310	DMT7G32	Discovery agent	N.A.	Investigative	[17]
PT-311	DM9ZCGX	Discovery agent	N.A.	Investigative	[17]
PT-312	DM7GN3E	Discovery agent	N.A.	Investigative	[17]
PT-313	DMN80XD	Discovery agent	N.A.	Investigative	[17]
PT-314	DM5C1ND	Discovery agent	N.A.	Investigative	[17]
PT-315	DMUK7IT	Discovery agent	N.A.	Investigative	[17]
PT-316	DMXM6NT	Discovery agent	N.A.	Investigative	[17]
PT-317	DM14XB7	Discovery agent	N.A.	Investigative	[17]
PT-319	DMKEPGN	Discovery agent	N.A.	Investigative	[17]
PT-320	DMV940C	Discovery agent	N.A.	Investigative	[17]
PT-322	DMIHSEV	Discovery agent	N.A.	Investigative	[17]
R-87027	DM2QN0S	Discovery agent	N.A.	Investigative	[95]
RTI-20	DMD3ST8	Discovery agent	N.A.	Investigative	[96]
Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one	DMNH3ST	Discovery agent	N.A.	Investigative	[97]
TNK-651	DMC958O	Discovery agent	N.A.	Investigative	[98]
UK-129485	DM6GLSF	Discovery agent	N.A.	Investigative	[99]
[(40-OH) MeLeu]4-CsA derivatives	DM9YHA7	Discovery agent	N.A.	Investigative	[100]
[(40-OH)MeLeu]4-Cyclosporin A	DM1ZM5R	Discovery agent	N.A.	Investigative	[100]
[(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A	DMV30N2	Discovery agent	N.A.	Investigative	[100]

References

• [1] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
• [5] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [6] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
• [8] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [9] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [10] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [11] Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
• [12] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [13] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [14] Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
• [15] Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7.
• [16] Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31.
• [17] Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
• [18] 127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52.
• [19] Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23.
• [20] Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8.
• [21] Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704.
• [22] EP patent application no. 2621528, Vaccine.
• [23] Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78.
• [24] Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8.
• [25] Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95.
• [26] Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8.
• [27] 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.
• [28] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [29] Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51.
• [30] In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9.
• [31] Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89.
• [32] Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9.
• [33] Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
• [34] Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193.
• [35] Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35.
• [36] Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9.
• [37] Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35.
• [38] ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health.
• [39] ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health.
• [40] WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors.
• [41] Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
• [42] Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives tr... Antiviral Res. 1995 Dec;28(4):331-42.
• [43] The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86.
• [44] Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatit... Antiviral Res. 2000 Dec;48(3):197-203.
• [45] Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res. 1996 Jun;31(1-2):115-20.
• [46] Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61.
• [47] Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother.2009 Feb;53(2):662-9.
• [48] Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8.
• [49] L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.. Antimicrob Agents Chemother. 1992 May; 36(5): 1019-1023.
• [50] 2 ,3 -Dialdehyde of ATP, ADP, and adenosine inhibit HIV-1 reverse transcriptase and HIV-1 replication. Curr HIV Res. 2014;12(5):347-58.
• [51] Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7.
• [52] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [53] EP patent application no. 0767664, Combination therapy for hiv infection.
• [54] Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7.
• [55] Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50.
• [56] Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 2011 Oct;20(10):1713-9.
• [57] Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin... J Biol Chem. 1991 Aug 5;266(22):14232-6.
• [58] A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257-66.
• [59] US patent application no. 5,830,759, Unique associated kaposi's sarcoma virus sequences and uses thereof.
• [60] DOI: 10.1038/scibx.2008.591
• [61] US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
• [62] Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775.
• [63] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394)
• [64] The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004 Dec;32(12):1359-69.
• [65] Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6.
• [66] Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology. 1997 Jan 15;116(1-3):77-88.
• [67] US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
• [68] New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996 May;30(2-3):109-24.
• [69] Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol. 2010 Oct 15;80(8):1133-40.
• [70] Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2597-601.
• [71] CN patent application no. 103360398, Triazolopyrimidine hiv-1 retrovirus inhibitor and its preparation method and application thereof.
• [72] WO patent application no. 2008,0165,22, Novel hiv reverse transcriptase inhibitors.
• [73] Single dose pharmacokinetics of SPD-756 in healthy adult volunteers, P F Smith, Poster Exhibition: The XIV International AIDS Conference: Abstract no. WePeB6050.
• [74] Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305.
• [75] Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998 Oct 13;37(41):14394-403.
• [76] Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
• [77] 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
• [78] Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
• [79] Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700.
• [80] Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J Med Chem. 1998 Sep 24;41(20):3793-803.
• [81] Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8.
• [82] Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. J Med Chem. 1992 Oct 16;35(21):3792-802.
• [83] Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63.
• [84] 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27.
• [85] HIV and reverse transcriptase inhibition by tanninsOriginal Research. Bioorg. Med. Chem. Lett. 2(12):1529-1534 (1992).
• [86] Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol Immunol. 1998;42(3):195-202.
• [87] Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9.
• [88] 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S... Bioorg Med Chem Lett. 2004 Jun 21;14(12):3173-6.
• [89] Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
• [90] Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
• [91] N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6.
• [92] 4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50.
• [93] New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3034-8.
• [94] Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7.
• [95] Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J Med Chem. 1998 Dec 17;41(26):5272-86.
• [96] Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem. 1991 Jul;34(7):2231-41.
• [97] Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9878-82.
• [98] Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651.Drug Res (Stuttg).2016 Apr;66(4):181-8.
• [99] Imidazo[2 3 :6,5]dipyrido[3,2-b:2 3 e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine, Bioorg. Med. Chem. Lett. 2(12):1745-1750(1992).
• [100] Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.